FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208991024> ?p ?o ?g. }

• W3208991024 abstract "Dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia. An affiliation was found between the initiation of myocardial injury ailment and long term treatment with dopamine D2 agonist drugs identified with the partial activation of 5-hydroxytryptamine receptor 2 A (5-HT2A). The investigation aimed to examine the activity of sarpogrelate (a 5-HT2A receptor blocker) in reducing myocardial injury prompted by extended haul utilisation of D2 receptor agonists in rats with alloxan-induced diabetes.Both bromocriptine and cabergoline were managed independently and combined with sarpogrelate for about a month in diabetic nephropathy rats. Both tail-cuff blood pressure and the BGL were recorded weekly. For all animals, the kidney hypertrophy index, serum creatinine, blood urea nitrogen, alanine transaminase, and aspartate transaminase levels were measured after one month of treatment. The severity of the cardiac injury was assessed by the estimation of lactate dehydrogenase-1 (LDH-1), cardiac troponin I, and tumor necrosis factor alpha 1 (TNF1). The triphenyltetrazolium chloride (TTC) staining method was used to determine the experimental myocardial infarction (MI) size.Bromocriptine and cabergoline created a significant reduction in BGL, BP, and kidney hypertrophy index in diabetic nephropathy rats. Administration of bromocriptine and cabergoline, alone, or in combination with sarpogrelate fundamentally diminished the blood concentrations of alkaline phosphatase (ALP), Aspartate aminotransferase (AST), urea, and creatinine. Bromocriptine and cabergoline alone showed a noteworthy increase in the LDH-1, Troponin I, and TNF1 levels in the serum (p < 0.05). Paradoxically, utilising bromocriptine or cabergoline with sarpogrelate treatment altogether decreased the levels of the myocardial biomarkers in the serum. A mix of bromocriptine or cabergoline with sarpogrelate diminished the level of the myocardial infarct size in the heart assessed through the TTC staining method.The examination demonstrated that the combined use of sarpogrelate with bromocriptine or cabergoline decreased the potential adverse effects of these two drugs on the myocardial tissues." @default.
• W3208991024 created "2021-11-08" @default.
• W3208991024 creator A5001743265 @default.
• W3208991024 creator A5028355300 @default.
• W3208991024 creator A5036857727 @default.
• W3208991024 creator A5038153690 @default.
• W3208991024 creator A5069650150 @default.
• W3208991024 creator A5071686726 @default.
• W3208991024 creator A5071739023 @default.
• W3208991024 date "2021-10-26" @default.
• W3208991024 modified "2023-10-08" @default.
• W3208991024 title "Therapeutic activity of sarpogrelate and dopamine D2 receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes" @default.
• W3208991024 cites W1596457615 @default.
• W3208991024 cites W1726093383 @default.
• W3208991024 cites W1899652451 @default.
• W3208991024 cites W1966778267 @default.
• W3208991024 cites W1970259340 @default.
• W3208991024 cites W1975365680 @default.
• W3208991024 cites W1977709905 @default.
• W3208991024 cites W1983814298 @default.
• W3208991024 cites W1986935249 @default.
• W3208991024 cites W1988077890 @default.
• W3208991024 cites W1990549067 @default.
• W3208991024 cites W1991117742 @default.
• W3208991024 cites W1992351691 @default.
• W3208991024 cites W1993320494 @default.
• W3208991024 cites W1998237043 @default.
• W3208991024 cites W2000767238 @default.
• W3208991024 cites W2002493285 @default.
• W3208991024 cites W2006695172 @default.
• W3208991024 cites W2024959588 @default.
• W3208991024 cites W2045616932 @default.
• W3208991024 cites W2056191807 @default.
• W3208991024 cites W2074560470 @default.
• W3208991024 cites W2075077439 @default.
• W3208991024 cites W2081568627 @default.
• W3208991024 cites W2085329742 @default.
• W3208991024 cites W2107582181 @default.
• W3208991024 cites W2115733722 @default.
• W3208991024 cites W2116196704 @default.
• W3208991024 cites W2123449426 @default.
• W3208991024 cites W2124101879 @default.
• W3208991024 cites W2146063550 @default.
• W3208991024 cites W2158419770 @default.
• W3208991024 cites W2161250885 @default.
• W3208991024 cites W2341605660 @default.
• W3208991024 cites W2396853896 @default.
• W3208991024 cites W2406871646 @default.
• W3208991024 cites W2410040424 @default.
• W3208991024 cites W2513479869 @default.
• W3208991024 doi "https://doi.org/10.1186/s40360-021-00526-6" @default.
• W3208991024 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8547108" @default.
• W3208991024 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34702339" @default.
• W3208991024 hasPublicationYear "2021" @default.
• W3208991024 type Work @default.
• W3208991024 sameAs 3208991024 @default.
• W3208991024 citedByCount "2" @default.
• W3208991024 countsByYear W32089910242021 @default.
• W3208991024 crossrefType "journal-article" @default.
• W3208991024 hasAuthorship W3208991024A5001743265 @default.
• W3208991024 hasAuthorship W3208991024A5028355300 @default.
• W3208991024 hasAuthorship W3208991024A5036857727 @default.
• W3208991024 hasAuthorship W3208991024A5038153690 @default.
• W3208991024 hasAuthorship W3208991024A5069650150 @default.
• W3208991024 hasAuthorship W3208991024A5071686726 @default.
• W3208991024 hasAuthorship W3208991024A5071739023 @default.
• W3208991024 hasBestOaLocation W32089910241 @default.
• W3208991024 hasConcept C126322002 @default.
• W3208991024 hasConcept C134018914 @default.
• W3208991024 hasConcept C2776856834 @default.
• W3208991024 hasConcept C2778176769 @default.
• W3208991024 hasConcept C2779064019 @default.
• W3208991024 hasConcept C2779832395 @default.
• W3208991024 hasConcept C2780306776 @default.
• W3208991024 hasConcept C71315377 @default.
• W3208991024 hasConcept C71924100 @default.
• W3208991024 hasConceptScore W3208991024C126322002 @default.
• W3208991024 hasConceptScore W3208991024C134018914 @default.
• W3208991024 hasConceptScore W3208991024C2776856834 @default.
• W3208991024 hasConceptScore W3208991024C2778176769 @default.
• W3208991024 hasConceptScore W3208991024C2779064019 @default.
• W3208991024 hasConceptScore W3208991024C2779832395 @default.
• W3208991024 hasConceptScore W3208991024C2780306776 @default.
• W3208991024 hasConceptScore W3208991024C71315377 @default.
• W3208991024 hasConceptScore W3208991024C71924100 @default.
• W3208991024 hasIssue "1" @default.
• W3208991024 hasLocation W32089910241 @default.
• W3208991024 hasLocation W32089910242 @default.
• W3208991024 hasLocation W32089910243 @default.
• W3208991024 hasLocation W32089910244 @default.
• W3208991024 hasLocation W32089910245 @default.
• W3208991024 hasOpenAccess W3208991024 @default.
• W3208991024 hasPrimaryLocation W32089910241 @default.
• W3208991024 hasRelatedWork W1977455281 @default.
• W3208991024 hasRelatedWork W1980179952 @default.
• W3208991024 hasRelatedWork W1985786391 @default.
• W3208991024 hasRelatedWork W2035004278 @default.
• W3208991024 hasRelatedWork W2043484070 @default.
• W3208991024 hasRelatedWork W2050232925 @default.
• W3208991024 hasRelatedWork W2072909375 @default.

• next